Aquiring the Evidence TEACH 2013 TRACK 1.  Therapy  Utility  Performance  Likelihood  Diagnosis  Utility  Performance  Likelihood  Prognosis.

Slides:



Advertisements
Similar presentations
Study Designs in Epidemiologic
Advertisements

Atrial fibrillation.
75 trials and 11 systematic reviews a day PCFDP November 2010 Chris Hooper-Lane, MA, AHIP Ebling Library University of Wisconsin-Madison Bastian H
Developing an Answerable Question
Maximizing IV Thrombolytic Therapy in Acute Ischemic Stroke Kamakshi Lakshminarayan, MD PhD Assistant Professor Neurology & Epidemiology University of.
1.A 33 year old female patient admitted to the ICU with confirmed pulmonary embolism. It was noted that she had elevated serum troponin level. Does this.
Cardioversion of Atrial Fibrillation Clinical Issues Christopher Granger, MD Director, Cardiac Care Unit Duke University Medical Center December 2007.
Surveillance of Heart Diseases and Stroke Using Centers for Medicare and Medicaid (CMS) Data: A Researcher’s Perspective Judith H. Lichtman, PhD MPH Associate.
Evidence Based Medicine Searching for Evidence. Evidence Based Practice: Steps 1.A sk focused clinical question 2.S earch for the best evidence 3.A ppraise/assess.
Hypertension in the Elderly
Decision Support for Quality Improvement
SIGN CHD In Scotland in the year ending 31 March 2006 over 10,300 patients died from CHD and 5,800 from cerebrovascular disease, with.
A stroke is the leading cause of permanent impairment and disability. Pending a radical cure, patients recovering from a stroke will continue to require.
1 Leveraging the Culture of Performance Excellence in Ontario’s Health System HSPRN is an inter-organization Network funded by the Ontario Ministry of.
Atrial Fibrillation Andreas Stein Robert Smith, M.D. August 11, 2003.
Clinical Trials “What you need to know” April 2, 2008.
HelpDesk Answers Dissecting the Clinical Question
Miguel Bussière With a little help from Dr. Jenkins and Dr. Burneo July 12, 2005 Introduction to UWO Evidence-Based Neurology.
Evidence Based Medicine
10 Points to Remember on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in AdultsTreatment of Blood Cholesterol to Reduce.
Study design P.Olliaro Nov04. Study designs: observational vs. experimental studies What happened?  Case-control study What’s happening?  Cross-sectional.
Maximizing IV Thrombolytic Therapy in Acute Ischemic Stroke Kamakshi Lakshminarayan, MD PhD Assistant Professor Neurology & Epidemiology University of.
Create an answerable question. P Patient or Problem I Intervention or Outcome C Comparison intervention or Exposure O Outcomes QuestionIs hormone replacement.
Incremental Decrease in Clinical Endpoints Through Aggressive Lipid Lowering (IDEAL) Trial IDEAL Trial Presented at The American Heart Association Scientific.
Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.
Clinical Writing for Interventional Cardiologists.
VSM CHAPTER 6: HARM Evidence-Based Medicine How to Practice and Teach EMB.
Rapid Fire Journal Club May 16, 2014 Sadie T. Velásquez.
HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.
Learning Objectives Identify the model to create a well-built Clinical Question Differentiate between the various Evidence- Based Care Types of Questions.
Day 2 Seminar Types of research articles. Original research article new knowledge for the first time.
VBWG HOPE-TOO: Results of the HOPE Study Extension.
Prognosis study EBM questions. Prognostic factors Characteristics of patient that may predict eventual outcome Several types: demographic (eg age) disease-specific.
Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) Trial PEACE Trial Presented at The American Heart Association Scientific Sessions.
EVALUATING u After retrieving the literature, you have to evaluate or critically appraise the evidence for its validity and applicability to your patient.
Evidence-Based Medicine: Tools, Techniques, Results Balakrishnan S.
Diagnosis of acute MI Pharmacologic therapy* Immediate angiography PTCAPTCA Other Rx *Antithrombin agents, antiplatelet agents, and fibrinolytic agents.
Impact of Multidisciplinary Team Care on Older People with Polypharmacy Liang-Kung Chen Center for Geriatrics and Gerontology Taipei Veterans General Hospital.
Perindopril Remodeling in Elderly with Acute Myocardial Infarction PREAMIPREAMI Presented at The European Society of Cardiology Hot Line Session, September.
THE MANAGEMENT OF ACUTE AF. DR TRENT LIPP ROYAL BRISBANE AND WOMEN’S AND LOGAN HOSPITALS GETTING AGGRESSIVE WITH AF.
Date of download: 5/28/2016 From: Optimal Timing of Coronary Invasive Strategy in Non–ST-Segment Elevation Acute Coronary Syndromes: A Systematic Review.
Bleeding After Initiation of Multiple Antithrombotic Drugs, Including Triple Therapy, in Atrial Fibrillation Patients Following Myocardial Infarction and.
Evidence-Based Medicine: A Basic Primer Kevin Bradford, M.L.S. Clinical Information Librarian Instructor Medical College of Georgia April 2007.
Date of download: 6/18/2016 From: Treatment of Anemia in Patients With Heart Disease: A Systematic Review Ann Intern Med. 2013;159(11): doi: /
Information Mastery Information management Determine usefulness Understand sources (jungle) Make decisions with your patient.
Introducing fibrinolysis as emergency therapy in Timergara hospital, Pakistan – what happens beyond the emergency department? Stefano Malinverni, Rosa.
Nephrology Journal Club The SPRINT Trial Parker Gregg
DIAGNOSIS No symptoms = no heart failure. DIAGNOSIS No symptoms = no heart failure.
HOPE: Heart Outcomes Prevention Evaluation study
Evaluating Sepsis Guidelines and Patient Outcomes
Figure 2.1 First-year hospital admission rates among incident dialysis patients, by annual & monthly cohorts Patients aged 18 years or older. Peer Report Dialysis.
IBH, Cost (Risk Adjusted)
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Anticoagulant Safety Remains a Problem Emergency Hospitalizations for Adverse Drug Events.
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Acute Heart Failure.
Introduction ESC Annual Meeting in Review: NOACs and NVAF: Real-World Data, Guidelines, and More.
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
COPD Exacerbations UCI Internal Medicine Mini-Lecture
West Essex Frailty Pathway: Heart Failure
SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Challenging the Myths in Heart Failure With Reduced Ejection Fraction
Essential Evidence Plus,
Factor Xa Inhibitors in PAD
Screening, Lipid Stabilization, and Placebo Run-in
earching the best evidence
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
ARISE Trial Aggressive Reduction of Inflammation Stops Events
Cohort and Community Surveillance Components
Presentation transcript:

Aquiring the Evidence TEACH 2013 TRACK 1

 Therapy  Utility  Performance  Likelihood  Diagnosis  Utility  Performance  Likelihood  Prognosis  Utility  Performance  Likelihood  Harm  Utility  Performance  Likelihood LINKING QUESTIONS TO STUDY DESIGNS  RCT  COHORT  CROSS-SECTIONAL  CASE CONTROL

 THERAPY  Utility  Performance  Likelihood  DIAGNOSIS  Utility  Performance  Likelihood  PROGNOSIS  Utility  Performance  Likelihood  HARM  Utility  Performance  Likelihood LINKING QUESTIONS TO STUDY DESIGNS  THERAPY  RCT  Cohort  DIAGNOSIS  RCT  Cross-Sectional  Observational  PROGNOSIS  RCT  Cohort  Cohort/Single Arm  HARM  Cohort, Case-Control  Cohort  Cohort/Single Arm

LINKING STUDY DESIGNS TO SOURCES

EBM SEARCH ENGINES

 QUESTION 1  Therapy/Utility  P: Elderly patients with acute, stable AF, but no structural heart disease presenting to the ED < 48 hours of onset  I: Rapid acting pharmacological agents safely titrated to effect  C: Alternative regimens safely titrated to effect  O: Likelihood of rate control or cardioversion, hospital admission, complications of uncontrolled AF, adverse reactions to drugs BACK TO THE CASE Practice Guidelines, Systematic Review, RCT, Non-randomized studies

 QUESTION 2  Prognosis/Likelihood  P: Elderly patients with acute, stable AF, but no structural heart disease presenting to the ED < 48 hours of onset  I: Observation over a 30-day period  C: N/A  O: Stroke, decompensated heart failure, MI, death BACK TO THE CASE Practice Guidelines, Systematic Review, Cohort, Control Arm of an RCT

 QUESTION 3  Harm/Likelihood  P: Elderly patients with acute, stable AF, but no structural heart disease presenting to the ED < 48 hours of onset  I: Cardioversion in ED with discharge and early follow-up  C: N/A  O: Short-term complications of cardioversion, embolic events, admission, other complications of AF BACK TO THE CASE Practice Guidelines, Systematic Review, Cohort, Single-Arm Study

 SUMMARY: NGC, GIN Dynamed  SYNTHESIS: DARE QUESTION 1

 SYNTHESIS: Pubmed  SINGLE STUDY: Pubmed QUESTION 2

QUESTION 3  SUMMARY: NGC  SINGLE STUDY: Pubmed